We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

95 hedge funds and large institutions have $147M invested in Aldeyra Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

345% more call options, than puts

Call options by funds: $1.96M | Put options by funds: $440K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3.12% less ownership

Funds ownership: 66.5% → 63.38% (-3.1%)

14% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 28

14% less funds holding

Funds holding: 111 → 95 (-16)

14% less capital invested

Capital invested by funds: $172M → $147M (-$24.9M)

39% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 36

Holders
95
Holders Change
-16
Holders Change %
-14.41%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
22
Increased
24
Reduced
28
Closed
36
Calls
$1.96M
Puts
$440K
Net Calls
+$1.52M
Net Calls Change
+$2.87M

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$3.34M
2
KCM
Knoll Capital Management
Florida
+$2.56M
3
Millennium Management
Millennium Management
New York
+$2.52M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.31M
5
PM
Prosight Management
Texas
+$2.01M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$7.72M
2
TLP
Tri Locum Partners
New York
-$6.43M
3
State Street
State Street
Massachusetts
-$2.42M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.81M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
E
26
Ergoteles
New York
$952K +$820K +238,500 New
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$936K +$807K +234,670 New
Deutsche Bank
28
Deutsche Bank
Germany
$916K -$228K -66,373 -22%
State Street
29
State Street
Massachusetts
$694K -$2.42M -703,916 -80%
PAI
30
Palo Alto Investors
California
$642K – – –
DCM
31
Dupont Capital Management
Delaware
$631K – – –
AC
32
Apogem Capital
New York
$596K +$156K +45,305 +44%
Bank of America
33
Bank of America
North Carolina
$529K +$142K +41,316 +45%
CAM
34
ClariVest Asset Management
California
$431K – – –
WC
35
Woodstock Corp
Massachusetts
$418K +$116K +33,736 +48%
CSS
36
Cubist Systematic Strategies
Connecticut
$368K +$269K +78,312 +560%
Northern Trust
37
Northern Trust
Illinois
$360K -$1.2M -349,301 -79%
Dimensional Fund Advisors
38
Dimensional Fund Advisors
Texas
$331K -$291K -84,699 -51%
WMSA
39
Weiss Multi-Strategy Advisers
New York
$320K -$171K -49,765 -38%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$314K -$452K -131,340 -63%
Marshall Wace
41
Marshall Wace
United Kingdom
$309K +$267K +77,681 New
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$288K +$105K +30,528 +73%
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$271K +$234K +67,914 New
CANY
44
Caxton Associates (New York)
New York
$231K +$199K +57,860 New
BFM
45
Boothbay Fund Management
New York
$224K +$9.87K +2,870 +5%
CL
46
CSS LLC
Illinois
$213K +$144K +42,000 +365%
PAG
47
Private Advisor Group
New Jersey
$196K +$169K +49,165 New
T. Rowe Price Associates
48
T. Rowe Price Associates
Maryland
$181K -$3.63K -1,054 -2%
GCM
49
Graham Capital Management
Connecticut
$169K +$146K +42,385 New
Thrivent Financial for Lutherans
50
Thrivent Financial for Lutherans
Minnesota
$164K +$141K +41,113 New
1
2
3 4 5

ALDX Hedge Fund Activity: Q2 2022 in Review

95 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2022, worth a combined $147M — down 14% from $172M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ALDX and 22 opened new positions — a net loss of 14 holders — while 28 trimmed existing stakes and 24 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.34M. The largest seller was BlackRock, cutting an estimated $7.72M.

  • 95 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2022, down from 111 in Q1 2022.
  • Funds reported $147M of Aldeyra Therapeutics stock for Q2 2022, down 14% quarter-over-quarter.
  • 22 funds opened new Aldeyra Therapeutics positions in Q2 2022 and 36 closed out, a net change of -14 holders.
  • The largest Aldeyra Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.34M added.
  • The largest Aldeyra Therapeutics seller in Q2 2022 was BlackRock, an estimated $7.72M sold.

Based on aggregated 13F filings for Q2 2022.